Journal of Antimicrobial Chemotherapy, Vol 41, 69-73, Copyright © 1998 by The British Society for Antimicrobial Chemotherapy
G Tatsis, G Tsoukalas, G Boulbasakos, E Platsouka, M Anagnostopoulou, M Pirounaki, O Paniara, E Sioula, J Raptis and G Saroglou
In an open, randomized, parallel group study, the efficacy and tolerance of
roxithromycin 300 mg po od was compared with clarithromycin 500 mg po bd in
the treatment of 60 patients with lower respiratory tract infections
(LRTI). The two groups were well-matched demographically. Fifty patients
(25 per group) were clinically evaluable at the end of the study and a
satisfactory response was found in 88% of those given roxithromycin and 80%
of those given clarithromycin. All had received treatment for a minimum of
3 days. Only one (3.3%) of 30 patients in the roxithromycin group reported
adverse events compared with seven (23.3%) of 30 in the clarithromycin
group. Thus both roxithromycin and clarithromycin are effective in the
treatment of LRTI but roxithromycin is better tolerated (P < 0.05) with
the advantage of a once-daily dose.
ORIGINAL ARTICLES
Efficacy and tolerance of roxithromycin versus clarithromycin in the treatment of lower respiratory tract infections
Evangelismos Hospital, Athens, Greece.
CiteULike 
Connotea 
Del.icio.us What's this?
Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.